Expected to supply much-needed capital, private placements have been a major disappointment so far. This may change.
Boosted by big pharma deals, the bank vaults to No. 1 on the M&A league table.
GAO says the insurer's toxic assets are worth a lot less than when the government bought them last year.
Bank finds itself in a pickle over documents wanted by a committee probing the Merrill deal.
Year-to-date issuance of $372 billion has already bested the full-year record set in 2001.
